Innovation begins from unique but simple idea
We focus on the immunity of cancer survivors, that enable them to eradicate cancer
What if we provide the survivor's Ab to other cancer patients?
The antibody expected to prevent metastasis or recurrence of the primary tumor, like in survivors
What is the biggest advantage for the survivor's Ab?
The survivor's Ab has been selected and stored in cancer patient's body, for its maximum efficacy and minimum toxicity. This feature is critical to reduce toxicity risk in the clinical trial
New paradigm in antibody drug discovery
Compared to conventional strategy, the CharisMab platform discovers unique antibody with potential to be first-in-class targeted therapeutic in various deadly cancer
conventional strategy for antitumor antibody discovery
Novel strategy of the CarisMab
Patent Status
List of the Original/International patents for the ChrisMab and SS-001
